Guideline Recommendations for Invasive Candidiasis and Aspergillosis in Adults
Invasive Candidiasis – First‑Line Therapy
- Echinocandins (caspofungin, micafungin, or anidulafungin) are the preferred initial agents for most adult patients, especially those who are critically ill, hemodynamically unstable, or have recent azole exposure. [@1]
- Recommended dosing:
- Caspofungin – 70 mg loading dose, then 50 mg daily. [@1][@3]
- Micafungin – 100 mg daily. [@1]
- Anidulafungin – 200 mg loading dose, then 100 mg daily. [@1]
- Fluconazole (800 mg loading, then 400 mg daily) is an acceptable alternative only for patients who are not critically ill, have no recent azole exposure, and are unlikely to harbor fluconazole‑resistant species. [@1]
Species‑Specific Considerations
- Candida albicans – Transition from an echinocandin to fluconazole is appropriate once the patient is clinically stable and susceptibility is confirmed. [@5][@1]
- Candida glabrata – Echinocandins are strongly preferred; azole switch is discouraged without documented susceptibility. [@5][@1]
- Candida parapsilosis – Fluconazole is preferred if the isolate is susceptible; continuation of an echinocandin is reasonable when the patient is improving. [@5]
- Candida krusei – Inherently resistant to fluconazole; use an echinocandin or voriconazole. [@5]
- Mandatory susceptibility testing for all bloodstream and clinically relevant Candida isolates. [@1]
Alternative Agents (When Echinocandins or Azoles Cannot Be Used)
- Amphotericin B deoxycholate – 0.5–1.0 mg/kg daily. [@5]
- Lipid‑formulation amphotericin B – 3–5 mg/kg daily. [@5][@3]
Treatment Duration and Monitoring
- Continue antifungal therapy for at least 2 weeks after documented clearance of Candida from the bloodstream and resolution of attributable symptoms. [@3][@6]
- Remove central venous catheters whenever feasible. [@3][@6]
- Perform an ophthalmologic examination to exclude endophthalmitis. [@6]
- Obtain abdominal imaging (CT or ultrasound) if candidemia persists to identify deep‑seated foci. [@6]
Chronic Disseminated Candidiasis (e.g., Hepatosplenic)
- Initial therapy – Lipid‑formulation amphotericin B (3–5 mg/kg daily) or an echinocandin for several weeks. [@3][@6]
- Step‑down therapy – Fluconazole 400 mg daily for isolates confirmed susceptible. [@3][@6]
- Duration – Continue until lesions resolve on repeat imaging, typically several months. [@3][@6]
Invasive Pulmonary Aspergillosis – Primary Therapy
- Voriconazole is the drug of choice. Loading: 6 mg/kg IV every 12 h for two doses; Maintenance: 4 mg/kg IV every 12 h or 200 mg orally every 12 h after stabilization. [@2]
Alternative Primary Agents (When Voriconazole Is Contraindicated)
- Liposomal amphotericin B – 3–5 mg/kg daily. [@2]
Combination vs. Monotherapy (Proven or Probable Disease)
- A conditional recommendation allows either combination therapy (mold‑active triazole + echinocandin) or monotherapy with a mold‑active triazole; this is based on low‑quality evidence and does not mandate routine combination use. [@7]
- In critically ill patients, combination therapy with caspofungin plus voriconazole or liposomal amphotericin B should be considered. [@2]
Salvage Therapy (Refractory Disease or Intolerance)
- Caspofungin (if not previously used). [@2]
- Liposomal amphotericin B (if not previously used). [@2]
- Posaconazole – 200 mg every 8 h orally. [@2]
Site‑Specific Considerations for Aspergillosis
- Central nervous system involvement – Voriconazole is preferred because of excellent CNS penetration; this form carries the highest mortality among aspergillosis presentations. [@2]
- Osteomyelitis / septic arthritis – Surgical debridement of devitalized tissue is essential alongside antifungal therapy. [@2]
- Endocarditis – Requires surgical resection of infected valves. [@2]
Duration of Aspergillosis Therapy
- Continue treatment until resolution or stabilization of all clinical and radiographic manifestations, which typically requires several months of therapy. [@2]
- Reversal of immunosuppression is critical for favorable outcomes. [@2]
Critical Care Considerations – Empiric Therapy & Prophylaxis
- Empiric antifungal therapy should be considered in critically ill ICU patients with risk factors for invasive candidiasis, no other source of fever, and signs of septic shock. [@3][@6]
- Routine prophylactic or empiric antifungal agents targeting Candida are conditionally recommended against in non‑neutropenic, non‑transplant ICU patients. [@7]
Drug‑Interaction Monitoring
- Voriconazole has significant CYP450 interactions and requires therapeutic drug monitoring. [@2]
Anidulafungin Recommendations for Invasive Candidiasis
Adult Dosing and First‑Line Use
- Loading dose 200 mg IV on day 1 followed by 100 mg IV daily is the recommended regimen for invasive candidiasis (including candidemia) in adults. This dosing is endorsed as first‑line therapy for most adult patients, especially those who are critically ill, hemodynamically unstable, or have recent azole exposure. Strong recommendation. 1, 2
- Preference over fluconazole in patients with moderately severe to severe illness, reflecting superior efficacy in this subgroup. Strong recommendation. 3
Treatment Duration
- Continue therapy for at least 2 weeks after documented clearance of Candida from blood and resolution of attributable symptoms. This minimum duration applies to all adult patients. Strong recommendation. 1, 4, 5
- In neutropenic patients, therapy should be maintained until neutropenia resolves in addition to the 2‑week minimum. Strong recommendation. 1, 5
Transition to Oral Therapy (De‑escalation)
- Switch to oral fluconazole after 5–7 days in clinically stable patients with fluconazole‑susceptible isolates (e.g., C. albicans) and negative repeat blood cultures. Strong recommendation. 2
- De‑escalation is strongly recommended once susceptibility is confirmed. Strong recommendation. 4, 3
- Do not transition to an azole for C. glabrata without documented susceptibility; maintain echinocandin therapy in this scenario. Strong recommendation. 1, 6
- For C. parapsilosis, continuation of the echinocandin is reasonable if the patient is clinically stable and follow‑up cultures are negative. Strong recommendation. 1, 6
Species‑Specific Considerations
- For Candida glabrata infections, anidulafungin (or another echinocandin) is strongly preferred throughout treatment. Strong recommendation. 1, 6
- Echinocandin susceptibility testing should be performed for C. glabrata or C. parapsilosis isolates, especially when prior echinocandin exposure is known. Strong recommendation. 2
- For Candida krusei, anidulafungin is recommended because the species is intrinsically resistant to fluconazole. Strong recommendation. 5
- Susceptibility testing is mandatory for all bloodstream and clinically relevant Candida isolates to guide therapy. Strong recommendation. 2
Empirical Therapy in Critically Ill Patients
- Empirical use of anidulafungin (200 mg loading, then 100 mg daily) is recommended for suspected invasive candidiasis in critically ill patients. Strong recommendation. 1, 4, 5
- Empirical echinocandin therapy is preferred in patients with recent azole exposure, moderately severe to severe illness, or high risk for C. glabrata or C. krusei. Strong recommendation. 6, 5
- Consider empirical therapy when critically ill patients have risk factors for invasive candidiasis and no other identifiable source of fever. Strong recommendation. 5